Evaluation of sildenafil pressurized metered dose inhalers as a vasodilator in umbilical blood vessels of chicken egg embryos

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 86, Issue 1, 2014, Pages 90-97

  Sawatdee, Somchai ^a   Hiranphan, Phetai ^a   Laphanayos, Kampanart ^b   Srichana, Teerapol ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b Technical Service   (Thailand)

Author keywords

Chicken egg embryo; Cyclodextrin; Development; Pressurized metered dose inhalers; Sildenafil citrate; Vasodilation

Indexed keywords

ALCOHOL; ALPHA CYCLODEXTRIN; BETA CYCLODEXTRIN; GAMMA CYCLODEXTRIN; MACROGOL 400; SILDENAFIL; SORBITAN OLEATE;

ARTICLE; CHICKEN; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; EGG; EMBRYO; IN VITRO STUDY; METERED DOSE INHALER; NONHUMAN; PRESSURIZED METERED DOSE INHALER; UMBILICAL CORD BLOOD; VASODILATATION;

CHICKEN EGG EMBRYO; CYCLODEXTRIN; DEVELOPMENT; PRESSURIZED METERED DOSE INHALERS; SILDENAFIL CITRATE; VASODILATION;

ANIMALS; BLOOD PRESSURE; BLOOD VESSELS; CHEMISTRY, PHARMACEUTICAL; CHICK EMBRYO; CYCLODEXTRINS; DRUG CARRIERS; EXCIPIENTS; HYPERTENSION, PULMONARY; METERED DOSE INHALERS; PIPERAZINES; PURINES; SOLUBILITY; SULFONES; UMBILICAL CORD; VASODILATION; VASODILATOR AGENTS;

EID: 84896732147     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.09.001     Document Type: Article

References (51)

1. A. Chockalingam, G. Gnanavelu, S. Venkatesan, S. Elangovan, V. Jagannathan, T. Subramaniam, R. Alagesan, and S. Dorairajan Efficacy and optimal dose of sildenafil in primary pulmonary hypertension Int. J. Cardiol. 99 2005 91 95
2. D.J. Nichols, G.J. Muirhead, and J.A. Harness Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality Br. J. Clin. Pharmacol. 53 2002 5S 12S
3. S.G. Raja, M.D. Danton, K.J. MacArthur, and J.C. Pollock Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence J. Cardiothor. Vasc. Anesth. 20 2006 722 735
4. K.M. Chin, and L.J. Rubin Pulmonary arterial hypertension J. Am. Coll. Cardiol. 51 2008 1527 1538
5. N. Galiè, M.M. Hoeper, M. Humbert, A. Torbicki, J.L. Vachiery, J.A. Barbera, M. Beghetti, P. Corris, S. Gaine, J.S. Gibbs, M.A. Gomez-Sanchez, G. Jondeau, W. Klepetko, C. Opitz, A. Peacock, L. Rubin, M. Zellweger, and G. Simonneau Guidelines for the diagnosis and treatment of pulmonary hypertension Eur. Heart J. 30 2009 2493 2537
6. M. Guazzi Sildenafil and phosphodiesterase-5 inhibitors for heart failure Curr. Heart Fail. Rep. 5 2008 110 114
7. R.M. Spring, S. Ulrich, L.C. Huber, R. Speich, M. Maggiorini, U. Treder, and M. Fischler Sildenafil for pulmonary hypertension: dose-dependent improvement in exercise performance Pulm. Pharmacol. Ther. 21 2008 516 521
8. S. Jung, Y. Seo, G.K. Kim, J.S. Woo, C.S. Yong, and H. Choi Comparison of the solubility and pharmacokinetics of sildenafil salts Arch. Pharm. Res. 34 3 2011 451 454
9. M. Mandegar, Y.C.B. Fung, W. Huang, C.V. Remillard, L.J. Rubin, and J.X.J. Yuan Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension Microvasc. Res. 68 2004 75 103
10. D. Montani, M.C. Chaumais, L. Savale, D. Natali, L.C. Price, X. Jaïs, M. Humbert, G. Simonneau, and O. Sitbon Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension Adv. Ther. 26 2009 813 825
11. M. Aubin, S. Laurendeau, A. Mommerot, Y. Lamarche, A. Denault, M. Carrier, and L.P. Perrault Differential effects of inhaled and intravenous sildenafil in the prevention of the pulmonary endothelial dysfunction due to cardiopulmonary bypass J. Cardiovasc. Pharmacol. 51 1 2008 11 17
12. F. Ichinose, J. Erana-Garcia, Y. Raveh, R. Jones, L. Krim, M.W. Clark, J.D. Winkler, K.D. Bloch, and W.M. Zapol Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension Crit. Care Med. 29 5 2001 1000 1005
13. H. Baquero, and A. Sola Intratracheal sildenafil in the newborn with pulmonary hypertension: in reply Pediatrics 119 2007 216
14. A.H. Elshafeey, E.R. Bendas, and O.H. Mohamed Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits AAPS PharmSciTech 10 2 2009 361 367
15. N. Jooste Extemporaneous preparation in a resource-limited setting: sildenafil citrate suspension S. Afr. Pharm. J. 78 8 2011 49 50
16. M.C. Nahata, R.S. Morosco, and M.T. Brady Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children Am. J. Health-Syst. Pharm. 63 1 2006 254 257
17. V.P. Patel, T.R. Desai, B.G. Chavda, and R.M. Katira Extemporaneous dosage form for oral liquids Pharmacophore 2 2 2011 86 103
18. B. Ramírez-Mendiola, L. Rivera-Espinosa, J. Chávez-Pacheco, R. Alemón-Medina, J. Bobadilla-Chávez, H. Osnaya-Martínez, C. Flores- Pérez, H. Juárez-Olguín, J. Flores-Pérez, and R. García-Alvarez Stability, content uniformity and therapeutic efficacy of sildenafil extemporaneous capsules Afr. J. Pharm. Pharmacol. 6 3 2012 162 168
19. S. Sawatdee, H. Phetmung, and T. Srichana Sildenafil citrate monohydrate-cyclodextrin nanosuspension complexes for use in metered-dose inhalers Int. J. Pharm. 455 2013 248 253
20. O. Pak, W. Janssen, H.A. Ghofrani, W. Seeger, F. Grimminger, R.T. Schermuly, and N. Weissmann Animal models of pulmonary hypertension: role in translational research Drug Discov. Today Dis. Models 7 3-4 2010 89 97
21. L.A. Matinez-Lemus, R.K. Hester, E.J. Becker, G.A. Ramirez, and T.W. Odom Pulmonary artery vasoactivity in Broiler and Leghorn chickens: an age profile Poult. Sci. 82 12 2003 1957 1964
22. C. McKenzie, A. MacDonald, and A.W. Shaw Mechanisms of U46619-induced contraction of rat pulmonary arteries in the presence and absence of the endothelium Br. J. Pharmacol. 157 2009 581 596
23. 18F]fluticasone propionate particles for drug deposition studies in humans with PET-formulation and analysis J. Labelled Compd. Rad. 47 2004 55 70
24. A. Khale, and A. Bajaj Formulation and development of metered dose inhalations of salbutamol in solution form Indian J. Pharm. Sci. 73 2011 543 549
25. S.S. Shrikhande, A. Rao, A. Ambekar, and A.N. Bajaj Metered dose inhalation formulations of salbutamol sulphate using non-CFC propellant tetrafluoroethane Int. J. Pharm. Sci. Drug Res. 3 2011 292 296
26. British Pharmacopoeia, British Pharmacopoeial Commission, London, 2011.
27. H.D.C. Smyth The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers Adv. Drug Deliver. Rev. 55 2003 2003 807 828
28. U.S. Pharmacopeial Convention, USP33-NF28, USP, Rockville MD, 2010.
29. P.T. White Experimental studies on the circulatory system of the late chick embryo J. Exp. Biol. 61 3 1974 571 592
30. K.M. Alkharfy Simple and sensitive LC-ESI-MS method for the quantitation of sildenafil in plasma samples J. Sep. Sci. 32 2009 3866 3870
31. S. Sawatdee, and T. Srichana Analytical validation of sildenafil citrate inhaler preparation Chiang Mai J. Sci. 40 2013 (in press)
32. A.J. Hickey Inhalation Aerosols: Physical and Biological Basis for Therapy second ed. 2007 Informa Healthcare New York
33. C. Kleinstreuer, Z. Zhang, and J.F. Donohue Targeted drug aerosol delivery in the human respiratory system Annu. Rev. Biomed. Eng. 10 2008 195 220
34. H.W. Faber, and J. Loscalzo Mechanism of disease: pulmonary hypertension N. Engl. J. Med. 351 2004 1655 1665
35. H. Steckel, and S. Wehle A novel formulation technique for metered dose inhaler (MDI) suspensions Int. J. Pharm. 284 2004 75 82
36. M.E. Brewster, and T. Loftsson Cyclodextrins as pharmaceutical solubilizers Adv. Drug Deliver. Rev. 59 2007 645 666
37. T. Loftsson, R. O'Fee, Cyclodextrins in solid dosage forms, in: E. Bolton (Ed.), Business Briefing: PharmaTech 2003, World Markets Research Centre, London, pp. 176-180.
38. R. Challa, A. Ahuja, J. Ali, and R.K. Khar Cyclodextrin in drug delivery: an updated review AAPS PharmSciTech 6 2005 E329 E357 (Article 43)
39. R. Arun, K.C.K. Ashok, and V.V.N.S.S. Sravanthi Cyclodextrins as drug carrier molecule: a review Sci. Pharm. 76 2008 567 598
40. B. Evrard, P. Bertholet, M. Gueders, M.P. Flament, G. Piel, L. Delattre, A. Gayot, P. Leterme, J.M. Foidart, and D. Catado Cyclodextrins as a potential carrier in drug nebulization J. Control. Release 96 2004 403 410
41. H. Maria, and C. Marques The use of cyclodextrins in formulations for lung delivery Inhalation 5 3 2011 22 26
42. V.J. Stella, and Q. He Cyclodextrins Toxicol. Pathol. 36 2008 30 42
43. B.R. Challa, B.Z. Awen, B.R. Chandu, M. Khagga, C.K. Bannoth, K. Kanala, R.P. Shaik, R. Peraman, and R. Gogineni Sildenafil and N-desmethyl sildenafil quantification in human plasma by HPLC coupled with ESI-MS/MS detection: application to bioequivalence study Anal. Methods 2 2010 1043 1050
44. M. Tseng, and J. Lin Determination of sildenafil citrate adulterated in a dietary supplement capsule by LC/MS/MS J. Food Drug Anal. 10 2 2002 112 119
45. J.D. Smet, K. Boussery, P.D. Cock, P.D. Paepe, J.P. Remon, M.V. Winckel, and J.V. Bocxlaer A bio-analytical hydrophilic interaction LC-MS/MS method for the simultaneous quantitation of omeprazole and lansoprazole in human plasma in support of a pharmacokinetic omeprazole study in children J. Sep. Sci. 33 2010 939 947
46. M. Dušek, M. Šanda, P. Cuhra, S. Baršova, Simultaneous LC-MS/MS determination of sildenafil and related analogues added illegally to herbal products intended for the treatment of erectile dysfunction, 2013. < http://dusekm.tripod.com/pdf/Poster-PDE-5-RAFA07-Prague-Martin- Dusek.pdf >.
47. A. Tracqui, and B. Ludes HPLC-MS for the determination of sildenafil citrate (Viagra®) in biological fluids. Application to the salivary extraction of sildenafil after oral intake J. Anal. Toxicol. 27 2003 88 94
48. J. Wang, Y. Wang, J.P. Fawcett, Y. Wang, and J. Gu Determination of omeprazole in human plasma by liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry J. Pharmaceut. Biomed. 39 2005 631 635
49. S.L. Archer, and E.D. Michelakis Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension N. Engl. J. Med. 361 2009 1864 1871
50. P.E. Subias, J.A. Barberá, and V. Suberviola Current diagnostic and prognostic assessment of pulmonary hypertension Rev. Esp. Cardiol. 63 5 2010 583 596
51. C.J. Rhodes, A. Davidson, J.S.R. Gibbs, J. Wharton, and M.R. Wilkins Therapeutic targets in pulmonary arterial hypertension Pharmacol. Therapeut. 121 2009 69 88